BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16986129)

  • 21. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
    Byrd JC; Ruppert AS; Mrózek K; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Stamberg J; Koduru PR; Moore JO; Mayer RJ; Davey FR; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Mar; 22(6):1087-94. PubMed ID: 15020610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
    Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
    Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution.
    Vey N; Bouabdallah R; Stoppa A; Faucher C; Lafage M; Chabannon C; Sainty D; Gastaut J; Maraninchi D; Blaise D
    Bone Marrow Transplant; 2004 Jan; 33(2):177-82. PubMed ID: 14647259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
    Farag SS; Archer KJ; Mrózek K; Vardiman JW; Carroll AJ; Pettenati MJ; Moore JO; Kolitz JE; Mayer RJ; Stone RM; Larson RA; Bloomfield CD
    Int J Oncol; 2002 Nov; 21(5):1041-51. PubMed ID: 12370753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
    Iriyama N; Hatta Y; Takeuchi J; Ogawa Y; Ohtake S; Sakura T; Mitani K; Ishida F; Takahashi M; Maeda T; Izumi T; Sakamaki H; Miyawaki S; Honda S; Miyazaki Y; Taki T; Taniwaki M; Naoe T
    Leuk Res; 2013 Sep; 37(9):1021-6. PubMed ID: 23810283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is translocation (8;21) a "favorable" cytogenetic rearrangement in acute myeloid leukemia?
    Fenaux P; Laï JL; Preudhomme C; Jouet JP; Deminatti M; Bauters F
    Nouv Rev Fr Hematol (1978); 1990; 32(3):179-82. PubMed ID: 2216701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
    Byrd JC; Lawrence D; Arthur DC; Pettenati MJ; Tantravahi R; Qumsiyeh M; Stamberg J; Davey FR; Schiffer CA; Bloomfield CD
    Clin Cancer Res; 1998 May; 4(5):1235-41. PubMed ID: 9607582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of adult AML with t(6;11)(q27;q23) by allogeneic hematopoietic SCT in the first CR.
    Tamai H; Yamaguchi H; Takahashi S; Tojo A; Hamaguchi H; Kobayashi T; Akiyama H; Sakamaki H; Okumura H; Nakao S; Arai A; Miura O; Tajika K; Inokuchi K; Dan K
    Bone Marrow Transplant; 2008 Oct; 42(8):553-4. PubMed ID: 18622415
    [No Abstract]   [Full Text] [Related]  

  • 32. Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
    Chevallier P; Labopin M; Nagler A; Ljungman P; Verdonck LF; Volin L; Zander AR; Finke J; Socie G; Cordonnier C; Harousseau JL; Mohty M; Rocha V;
    Bone Marrow Transplant; 2009 Nov; 44(9):589-94. PubMed ID: 19349953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
    Saito T; Usui N; Dobashi N; Maki N; Asai O; Yano S; Kato A; Watanabe H; Katori M; Nagamine M; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Kuraishi Y
    Rinsho Ketsueki; 1998 Jul; 39(7):481-6. PubMed ID: 9750454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
    Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
    Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristic clinical features and treatment of acute myelocytic leukemia with 8;21 translocation].
    Kyo T
    Rinsho Ketsueki; 1994 Mar; 35(3):245-9. PubMed ID: 8158843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report.
    Berger M; Ferrero I; Vassallo E; Gastaldo L; Carraro F; Biasin E; Madon E; Fagioli F
    Pediatr Hematol Oncol; 2005; 22(7):597-608. PubMed ID: 16166053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.